Study results suggest allogeneic SCT as standard consolidation therapy in pediatric patients with progression during frontline therapy or relapse of a CD3-positive ALCL.
Researchers in the Netherlands conducted HOVON-84 to determine what benefit, if any, early rituximab intensification had in adult patients with untreated DLBCL.
The overall response rate was 95.9%, with 100% of patients in the TN group and 93.9% of patients in the RR group responding.
A prospective NCTN PET-directed analysis aimed to eradicate the short- and long-term toxicities associated with RT in patients with limited-stage DLBCL.
The authors noted that these findings should be seen as a reference for the mutational landscape in MCL at baseline and at disease progression after treatment.
Researchers examine how far follicular lymphoma treatment has come, what limitations still remain, and where the management of the disease is headed.
For pediatric high-risk B-cell NHL, adding rituximab to standard LMB chemotherapy prolongs event-free and overall survival but may increase adverse events.
Higher graft CD34+ cell content is linked to improved platelet and neutrophil recovery after high-dose therapy.
Researchers compared the efficacy and nephrotoxicity of R-DHAP vs R-DHAOx among patients treated for NHL between 2007 and 2014.
Hypercalcemia is not uncommon in patients with de novo diffuse large B-cell lymphoma and may be linked to a higher risk for other adverse events.
